Factors associated with viral rebound among COVID-19 patients receiving oral antivirals
Open Access
- 8 March 2023
- journal article
- research article
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 122 (8) , 766-775
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health and Welfare (MOHW111-TDU-B-211-134002)
- National Taiwan University Hospital (NTUH.MM022-1)
- Ministry of Science and Technology, Taiwan (111-2321-B-002-017)
- Ministry of Science and Technology, Taiwan (111-2740-B-002-006)
This publication has 25 references indexed in Scilit:
- Update to living WHO guideline on drugs for covid-19BMJ, 2022
- Prospective health surveillance for COVID-19 among health care workers at a university medical center in Taiwan, January to June 2020Journal of the Formosan Medical Association, 2022
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19New England Journal of Medicine, 2022
- The T cell immune response against SARS-CoV-2Nature Immunology, 2022
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsNew England Journal of Medicine, 2021
- D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike CleavagemBio, 2021
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009